Mankind Pharma Future Growth
Future criteria checks 2/6
Mankind Pharma is forecast to grow earnings and revenue by 15.5% and 18.2% per annum respectively. EPS is expected to grow by 15.1% per annum. Return on equity is forecast to be 18.3% in 3 years.
Key information
15.5%
Earnings growth rate
15.1%
EPS growth rate
| Pharmaceuticals earnings growth | 17.9% |
| Revenue growth rate | 18.2% |
| Future return on equity | 18.3% |
| Analyst coverage | Good |
| Last updated | 12 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2027 | 173,492 | 30,371 | 33,797 | 37,526 | 11 |
| 3/31/2026 | 153,203 | 23,849 | 27,667 | 31,152 | 11 |
| 3/31/2025 | 124,493 | 20,996 | -67,731 | 26,663 | 11 |
| 9/30/2024 | 110,180 | 21,150 | 19,107 | 23,229 | N/A |
| 6/30/2024 | 106,496 | 19,625 | N/A | N/A | N/A |
| 3/31/2024 | 103,348 | 19,129 | 17,701 | 21,524 | N/A |
| 12/31/2023 | 99,463 | 17,271 | N/A | N/A | N/A |
| 9/30/2023 | 94,303 | 15,575 | 14,862 | 20,644 | N/A |
| 6/30/2023 | 91,481 | 14,762 | N/A | N/A | N/A |
| 3/31/2023 | 87,494 | 12,819 | 9,812 | 18,133 | N/A |
| 12/31/2022 | 84,225 | 11,865 | -15,564 | 10,901 | N/A |
| 3/31/2022 | 77,816 | 14,335 | -14,257 | 9,198 | N/A |
| 3/31/2021 | 62,144 | 12,654 | 8,249 | 11,372 | N/A |
| 3/31/2020 | 58,719 | 10,304 | 8,442 | 10,722 | N/A |
| 3/31/2019 | 49,800 | 5,785 | 3,027 | 6,004 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 543904's forecast earnings growth (15.5% per year) is above the savings rate (6.7%).
Earnings vs Market: 543904's earnings (15.5% per year) are forecast to grow slower than the Indian market (17.9% per year).
High Growth Earnings: 543904's earnings are forecast to grow, but not significantly.
Revenue vs Market: 543904's revenue (18.2% per year) is forecast to grow faster than the Indian market (10.5% per year).
High Growth Revenue: 543904's revenue (18.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 543904's Return on Equity is forecast to be low in 3 years time (18.3%).